Phase II study shows blinatumomab achieves minimal residual disease response in ALL

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Nicola Gökbuget (University Hospital Frankfurt, Frankfurt, Germany) presents the results of the single-arm phase II study that evaluated the Bispecific T-Cell Engager (BiTE) antibody construct (anti-CD19) blinatumomab in patients with minimal residual disease B-precursor acute lymphoblastic leukaemia (ALL).

Year of Production:
Running Time:
Color/Sound:

2014
09:36
Color/Sound

Comments are closed.